Chagas disease (CD) is caused by the protozoan parasite Trypanosoma cruzi that infects a
broad range of triatomines and mammalian species, including man. It afflicts 8 million …

Although the phosphorus atom is found in a variety of oxidation states, most of the
phosphorus‐containing molecules of pharmacological importance possess phosphorus in …

Chagas disease, a chronic systemic parasitosis caused by the Kinetoplastid protozoon
Trypanosoma cruzi, is the first cause of cardiac morbidity and mortality in poor rural and …

Research efforts on the medicinal chemistry of vanadium have been mainly focused whether
on improving biodistribution and tolerability of the vanadium insulin-enhancing core or on …

Eight new ruthenium complexes of clotrimazole (CTZ) with high antiparasitic activity have
been synthesized, cis, fac-[RuIICl2 (DMSO) 3 (CTZ)](1), cis, cis, trans-[RuIICl2 (DMSO) 2 …

The protozoan parasite, Trypanosoma cruzi, causes the most prevalent parasitic infection in
the American continent. It gives rise to life-long infection in humans and results in severe …

The cysteine protease cruzipain is essential for the viability, infectivity, and virulence of
Trypanosoma cruzi, the causative agent of Chagas disease. Thus, inhibitors of cruzipain are …

There are at least two obvious features that must be considered upon targeting specific
metabolic pathways/enzymes for drug development: the pathway must be essential and the …

A group of seventeen communicable and poverty-related diseases are considered
neglected by the World Health Organization due to the restricted development of diagnostic …

In our ongoing search for new metal-based chemotherapeutic agents against leishmaniasis
and Chagas disease, six new ruthenium–ketoconazole (KTZ) complexes have been …